NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for LORVIQUA® (lorlatinib, approved in the U.S., Canada, and Japan under the brand name LORBRENA®), an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI). The CHMP has adopted a positive opinion recommending conditional marketing authorization for LORVIQUA as monotherapy for the treatment of adult pat
Fri Mar 01, 2019 15:35
STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR™ (methylphenidate hydrochloride) extended-release capsules CII, a central nervous system (CNS) stimulant, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older. In a simulated Adult Workplace Environment (AWE) study, Adhansia XR demonstrated statistically significant improveme
Fri Mar 01, 2019 15:30
SALT LAKE CITY--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Utah?src=hash" target="_blank"gt;#Utahlt;/agt;--Recursion and the University of Utah’s Center for Technology & Venture Commercialization to launch incubator for life science and technology startups.
Fri Mar 01, 2019 15:00
DUBLIN--(BUSINESS WIRE)--The "Alopecia - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Alopecia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, r
Fri Mar 01, 2019 14:59
DUBLIN--(BUSINESS WIRE)--The "Bladder Pain - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Bladder Pain development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indicat
Fri Mar 01, 2019 14:55
DUBLIN--(BUSINESS WIRE)--The "Anthrax - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anthrax development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, rout
Fri Mar 01, 2019 14:48
DUBLIN--(BUSINESS WIRE)--The "Vulvar Cancer - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Vulvar Cancer development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indic
Fri Mar 01, 2019 14:46
DUBLIN--(BUSINESS WIRE)--The "Sinusitis - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sinusitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications,
Fri Mar 01, 2019 14:36
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and
Fri Mar 01, 2019 14:30
WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte Corporation (NASDAQ: INCY) ha anunciado presentará siete resúmenes de su cartera de investigación sobre el cáncer en el próximo Congreso anual de la American Association for Cancer Research (AACR) 2019. El Congreso se celebrará del 29 de marzo al 3 de abril de 2019 en el Georgia World Congress Center, en Atlanta (Georgia). Los resúmenes aceptados incluyen datos de los estudios clínicos del anticuerpo monoclonal anti-PD-1, INCMGA00121, de Incyte, en
Fri Mar 01, 2019 14:11
LEXINGTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;--Concert presents interim CTP-543 Phase 2 data in alopecia areata during Late-Breaker Session at AAD.
Fri Mar 01, 2019 14:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου